INMUNOENSAYO PARA DETERMINAR ANTICUERPOS IGG/IGM ESPECIFICOS FRENTE A VCA (VIRAL CAPSIDE ANTIGEN) DE VIRUS EPSTEIN-BARR
Mexico·Clase I·III. Agentes de diagnóstico·KABLA COMERCIAL,
S.A. DE C.V.·Registered December 13, 2022- Risk Class / Clase de Riesgo
- Clase I
- Product Type (Spanish)
- III. Agentes de diagnóstico
- Product Type (English)
- III. Agentes de diagnóstico
- Trade Name (Spanish)
- EPSTEIN-BARR VCA VIRCLIA® IGG/IGM MONOTEST
- Trade Name (English)
- EPSTEIN-BARR VCA VIRCLIA® IGG/IGM MONOTEST
- Analysis ID
- 1564R2022 SSA
- Registration Date
- December 13, 2022
- Name (Spanish)
- KABLA COMERCIAL, S.A. DE C.V.
- Name (English)
- KABLA COMERCIAL, S.A. DE C.V.
Access comprehensive regulatory information for INMUNOENSAYO PARA DETERMINAR ANTICUERPOS IGG/IGM ESPECIFICOS FRENTE A VCA (VIRAL CAPSIDE ANTIGEN) DE VIRUS EPSTEIN-BARR (INMUNOENSAYO PARA DETERMINAR ANTICUERPOS IGG/IGM ESPECIFICOS FRENTE A VCA (VIRAL CAPSIDE ANTIGEN) DE VIRUS EPSTEIN-BARR) in the Mexico medical device market through Pure Global AI's free database. This Clase I medical device is registered under COFEPRIS analysis ID 1564R2022 SSA and manufactured by KABLA COMERCIAL, S.A. DE C.V.. The device was registered on December 13, 2022.
This page provides complete registration details including product type (III. Agentes de diagnóstico), manufacturer information, and regulatory compliance data from the official Mexico COFEPRIS medical device database. Pure Global AI offers free access to Mexico's complete medical device registry with bilingual Spanish/English support, helping global MedTech companies navigate COFEPRIS regulations efficiently.